Scroll to top
- Follow Us
- –

̍̍ CSE: BRAX
̍̍ OTC: BRAXF
̍̍ FWB: 4960

©2022 Braxia Scientific Corp.

DISCLAIMER — The information on this site should not be used to make decisions about medical treatments. Please conduct your own research and due diligence before making any major health changes. Braxia Scientific, its members, directors, employees, and representatives are not responsible for damages of any nature arising out of or relating to the use of this website or any hyperlinked websites. The material that appears on this website is for informational purposes only. Braxia Scientific has made every effort to provide useful and accurate information. However, errors may appear from time to time. Braxia Scientific and its information providers make no warranty as to the reliability, timeliness, completeness, accuracy or usefulness of the information on the website. Any opinion, view, or idea contained in an article, story or column published on this website is that of the author and does not reflect or represent the views of Braxia Scientific or any of its members, directors, employees and representatives.

Go back

3 min read

INTERIM CHIEF FINANCIAL OFFICER

Published on December 8, 2020

Home
News Releases
INTERIM CHIEF FINANCIAL OFFICER

CHAMPIGNON BRANDS APPOINTS CHRISTOPHER HOBBS AS INTERIM CHIEF FINANCIAL OFFICER

VANCOUVER, BRITISH COLUMBIA (December 8, 2020) – Champignon Brands Inc. (the “Company”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), today announced that Christopher Hobbs will join the Company as Interim Chief Financial Officer (CFO), effective December 8, 2020. Stephen Brohman, the Company’s current contract CFO, has resigned from the position, effective December 7, 2020.

Mr. Brohman has agreed to assist the Company in order to ensure a smooth transition to a new fulltime CFO and the company appreciates Mr. Brohman’s cooperation in that regard.

Mr. Hobbs’ appointment is pending the recruitment and appointment of a full-time CFO as the Company announced on November 24, 2020.

Christopher Hobbs has acted as CFO for several public and private companies operating in the resource, health sciences and technology sectors. Mr. Hobbs is a member of the Chartered Accountants of Ontario and holds a Bachelor of Business Administration Degree from the Schulich School of Business at York University.

Dr. Roger McIntyre, Chief Executive Officer, Champignon Brands said, “Chris brings a depth of experience and expertise relevant to Champignon Brands at this critical time.”

Mr. Hobbs acknowledged Champignon Brands goal to become a global leader in breakthrough treatment for depression and other mental health conditions, noting “the priority now is to work diligently to complete the BCSC continuous disclosure review.”

Champignon Brands Inc. (http://braxiascientific.com) is a research-driven Company specializing in breakthrough ketamine treatment for depression, and other mental health conditions and its suicidal implications as well as delivery platforms for other health products. The Company works closely with subsidiaries that include AltMed Capital Corp. (“AltMed). The Canadian Rapid Treatment Center of Excellence is wholly owned by AltMed.

Investors: [email protected]
Media: Victoria Ollers, [email protected], 416 822-2288

Symbols – CSE: BRAX OTC: BRAXF FWB: 496

Next Post

CHANGES AT THE TOP

News Releases

Braxia Scientific Reports a 26% Increase in Total Treatment Volumes in F2023 and an 87% Increase in Treatments at Newly Expanded Ottawa Clinic

Company Taking Strategic Actions to Prioritize Clinic Expansion, Enhance Operational Effectiveness and Right Size Cost Structure. TORONTO, ONTARIO Monday June 12, 2023 – Braxia Scientific Corp. (“Braxia”, or the“Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with mentalhealth clinics providing innovative ketamine and psilocybin treatments for depression and relateddisorders, is pleased to report treatment volumes across its clinics increased 26.2% to 3,516 from2,785 treatments on a year-over-year basis in Fiscal 2023. The Company continues to experienceincreased demand across all of it 5 clinics. At its new Ottawa clinic, treatment volumes increased87.2% to 571 from 305 treatments on a year-over-year basis following the completion of constructionand opening of its expanded purpose-built clinic in late 2022. Additionally, its Kitchener-Waterlooclinic, opened in mid-2022, continues to see rapid increases in treatment volume, reaching 214treatments in its first 8 months of operation.“Over...

News Releases

Braxia Scientific Reports Fiscal 2023 Financial Results

Braxia Health ketamine treatments up 26% YoY in 2023 and revenue up 27% YoY Company completes dosing of final participant in Phase 2, multi-dose Psilocybin trial, results expected to be published prior to end of 2023 Company reviewing financing options, strategic partnerships and further cost reductions and organizational changes as required TORONTO, ONTARIO July 31, 2023 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and twelve months ended March 31, 2023. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for...